Drug Profile
Bapotulimab - Compugen
Alternative Names: BAY-1905254; CGEN-15001T program; CGEN-15001T-targeted mAb; CGEN-15001T-targeted monoclonal antibodyLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Compugen
- Developer Bayer HealthCare
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours; Squamous cell cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)